coagulation factor VII

• 凝固第VII因子

関

blood coagulation factor VII、factor VII、stable factor

WordNet

1. be a contributing factor; "make things factor into a companys profitability"
2. any of the numbers (or symbols) that form a product when multiplied together
3. an independent variable in statistics
4. anything that contributes causally to a result; "a number of factors determined the outcome"
5. consider as relevant when making a decision; "You must factor in the recent developments" (同)factor in, factor out
6. resolve into factors; "a quantum computer can factor the number 15" (同)factor in, factor out
7. an event known to have happened or something known to have existed; "your fears have no basis in fact"; "how much of the story is fact and how much fiction is hard to tell"
8. a concept whose truth can be proved; "scientific hypotheses are not facts"
9. a piece of information about circumstances that exist or events that have occurred; "first you must collect all the facts of the case"
10. a statement or assertion of verified information about something that is the case or has happened; "he supported his argument with an impressive array of facts"
11. the 22nd letter of the Roman alphabet (同)v

PrepTutorEJDIC

1. (…の)『要因』,(…を生み出す)要素《+『in』+『名』(do『ing』)》 / 囲数,約数 / 代理人,《おもに英》仲買人 / =factorize
2. 〈C〉『事実』,実際にある(あった)事 / 〈U〉真相,真実(truth) / 《the~》(法律用語で)犯行
3. vanadium の化学記号
4. 凝固,凝結
5. Virgin Islands

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/08/24 09:41:54」(JST)

wiki en

[Wiki en表示]

Coagulation factor VII (serum prothrombin conversion accelerator)
Anchoring of coagulation factor VIIa (PDB 1dan) to the membrane through its Gla domain
Available structures PDB Ortholog search: PDBe, RCSB List of PDB id codes 1BF9, 1CVW, 1DAN, 1DVA, 1F7E, 1F7M, 1FAK, 1FF7, 1FFM, 1J9C, 1JBU, 1KLI, 1KLJ, 1NL8, 1O5D, 1QFK, 1W0Y, 1W2K, 1W7X, 1W8B, 1WQV, 1WSS, 1WTG, 1WUN, 1WV7, 1YGC, 1Z6J, 2A2Q, 2AEI, 2AER, 2B7D, 2B8O, 2BZ6, 2C4F, 2EC9, 2F9B, 2FIR, 2FLB, 2FLR, 2PUQ, 2ZP0, 2ZWL, 2ZZU, 3ELA, 3TH2, 3TH3, 3TH4, 4IBL, 4ISH, 4ISI, 4JYU, 4JYV, 4JZD, 4JZE, 4JZF, 4NA9, 4NG9, 4NGA, 4X8S, 4X8T, 4X8U, 4X8V, 4YT6, 4YT7
Identifiers
Symbols	F7 ; SPCA
External IDs	OMIM: 613878 MGI: 109325 HomoloGene: 7710 ChEMBL: 3991 GeneCards: F7 Gene
EC number	3.4.21.21
Gene ontology Molecular function • glycoprotein binding • serine-type endopeptidase activity • receptor binding • calcium ion binding • protein binding • serine-type peptidase activity Cellular component • extracellular region • extracellular space • endoplasmic reticulum lumen • Golgi lumen • plasma membrane • vesicle Biological process • positive regulation of leukocyte chemotaxis • proteolysis • blood coagulation • blood coagulation, extrinsic pathway • circadian rhythm • positive regulation of platelet-derived growth factor receptor signaling pathway • peptidyl-glutamic acid carboxylation • positive regulation of blood coagulation • positive regulation of cell migration • organ regeneration • response to vitamin K • response to estrogen • post-translational protein modification • cellular protein metabolic process • positive regulation of positive chemotaxis • positive regulation of protein kinase B signaling • response to growth hormone Sources: Amigo / QuickGO
RNA expression pattern
More reference expression data
Orthologs
Species	Human	Mouse
Entrez	2155	14068
Ensembl	ENSG00000057593	ENSMUSG00000031443
UniProt	P08709	P70375
RefSeq (mRNA)	NM_000131	NM_010172
RefSeq (protein)	NP_000122	NP_034302
Location (UCSC)	Chr 13: 113.11 – 113.12 Mb	Chr 8: 13.03 – 13.04 Mb
PubMed search	[1]	[2]

Factor VII (EC 3.4.21.21, blood-coagulation factor VIIa, activated blood coagulation factor VII, formerly known as proconvertin) is one of the proteins that causes blood to clot in the coagulation cascade. It is an enzyme of the serine protease class. A recombinant form of human factor VIIa (eptacog alfa [activated], NovoSeven) has U.S. Food and Drug Administration approval for uncontrolled bleeding in hemophilia patients. It is sometimes used unlicensed in severe uncontrollable bleeding, although there have been safety concerns. A biosimilar form of recombinant activated factor VII (AryoSeven) is also available, but does not play any considerable role in the market.

Physiology

The main role of factor VII (FVII) is to initiate the process of coagulation in conjunction with tissue factor (TF/factor III). Tissue factor is found on the outside of blood vessels - normally not exposed to the bloodstream. Upon vessel injury, tissue factor is exposed to the blood and circulating factor VII. Once bound to TF, FVII is activated to FVIIa by different proteases, among which are thrombin (factor IIa), factor Xa, IXa, XIIa, and the FVIIa-TF complex itself. The complex of factor VIIa with TF catalyzes the conversion of factor IX and factor X into the active proteases, factor IXa and factor Xa, respectively.

The action of the factor is impeded by tissue factor pathway inhibitor (TFPI), which is released almost immediately after initiation of coagulation. Factor VII is vitamin K dependent; it is produced in the liver. Use of warfarin or similar anticoagulants decreases hepatic synthesis of FVII.

Genetics

The gene for factor VII is located on chromosome 13 (13q34).

Role in disease

Deficiency is rare (congenital proconvertin deficiency) and inherits recessively. Factor VII deficiency presents as a hemophilia-like bleeding disorder. It is treated with recombinant factor VIIa (NovoSeven or AryoSeven).

Medical uses

Recombinant factor VIIa, marketed under the trade names AryoSeven and NovoSeven, is used for people with hemophilia (with Factor VIII or IX deficiency) who have developed inhibitors against replacement coagulation factor.

It has also been used in the setting of uncontrollable hemorrhage, but its role in this setting is controversial with insufficient evidence to support its use outside of clinical trials. The first report of its use in hemorrhage was in an Israeli soldier with uncontrollable bleeding in 1999. Risks of its use include an increase in arterial thrombosis.

Recombinant human factor VII while initially looking promising in intracerebral hemorrhage failed to show benefit following further study and this is no longer recommended.

Interactions

Factor VII has been shown to interact with tissue factor.

References

Further reading

• Broze GJ, Majerus PW (1980). "Purification and properties of human coagulation factor VII". J. Biol. Chem. 255 (4): 1242–7. PMID 7354023. 
• Versteeg HH, Peppelenbosch MP, Spek CA (2002). "The pleiotropic effects of tissue factor: a possible role for factor VIIa-induced intracellular signalling?". Thromb. Haemost. 86 (6): 1353–9. PMID 11776298. 
• Golino P (2003). "The inhibitors of the tissue factor:factor VII pathway". Thromb. Res. 106 (3): V257–65. doi:10.1016/S0049-3848(02)00079-8. PMID 12356487. 

External links

• Official website
• The MEROPS online database for peptidases and their inhibitors: S01.215

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

• 1. 止血の概要 overview of hemostasis
• 2. 肝臓の合成能の検査（アルブミン、凝固因子、プロトロンビン時間など） tests of the livers biosynthetic capacity eg albumin coagulation factors prothrombin time
• 3. 血漿分画製剤および組換えDNA産生凝固因子 plasma derivatives and recombinant dna produced coagulation factors
• 4. 凝固検査の臨床使用 clinical use of coagulation tests
• 5. 心血管疾患の危険因子の概要 overview of the possible risk factors for cardiovascular disease

English Journal

• Blood as the carrier of ischemic tolerance in rat brain.

• Bonova P1, Gottlieb M1.
• Journal of neuroscience research.J Neurosci Res.2015 Aug;93(8):1250-7. doi: 10.1002/jnr.23580. Epub 2015 Mar 18.
• This study provides clear evidence that the factor inducing tolerance to ischemia is transmitted via the circulating blood. By using the remote ischemia and the cross-circulation model, the tolerance to ischemia was transmitted from donor to recipient. For this study, the following experimental grou
• PMID 25787695

• Ageing shows a pattern of cerebellar degeneration analogous, but not equal, to that in patients suffering from cerebellar degenerative disease.

• Hulst T1, van der Geest JN2, Thürling M3, Goericke S4, Frens MA1, Timmann D3, Donchin O5.
• NeuroImage.Neuroimage.2015 Aug 1;116:196-206. doi: 10.1016/j.neuroimage.2015.03.084. Epub 2015 Apr 18.
• Ageing generally leads to impairments in cognitive function and the ability to execute and learn new movements. While the causes of these impairments are often multi-factorial, integrity of the cerebellum in an elderly population is an important predictive factor of both motor function and cognitive
• PMID 25896930

• Constitutively expressed ERF-VII transcription factors redundantly activate the core anaerobic response in Arabidopsis thaliana.

• Bui LT1, Giuntoli B2, Kosmacz M3, Parlanti S4, Licausi F5.
• Plant science : an international journal of experimental plant biology.Plant Sci.2015 Jul;236:37-43. doi: 10.1016/j.plantsci.2015.03.008. Epub 2015 Mar 21.
• Plant adaptation to hypoxic conditions is mediated by the transcriptional activation of genes involved in the metabolic reprogramming of plant cells to cope with reduced oxygen availability. Recent studies indicated that members of the group VII of the Ethylene Responsive Transcription Factor (ERFs)
• PMID 26025519

Japanese Journal

• PT測定における検体保存の影響

• 桝谷 亮太,田中 秀磨,池本 敏行,田窪 孝行
• 医学検査 63(5), 535-544, 2014
• … 存によって起こる第VII因子のcold activationによりPTの測定秒数が短縮することが挙げられている2),3)．今回，検体の保存条件（温度と容器の種類）がPT，ヘパプラスチンテストhepaplastin test（HPT），トロンボテストthrombotest（TT）の測定秒数と凝固因子活性値に及ぼす影響を検討した．プラスチック容器保存の場合，室温，氷冷ともに検体採取直後に比べ8時間後のPTの測定秒数と第VII因子活性値に影響は …
• NAID 130004709165

• 凝固障害に対する補充療法-標準的治療法の整理

• 松下 正
• 日本輸血細胞治療学会誌 = Japanese journal of transfusion and cell therapy 59(4), 571-578, 2013-08-15
• NAID 10031190745

• 肉眼的血尿,前立腺生検後の皮下出血を契機に診断された後天性血友病の1例

• 木村 博子,植垣 正幸,青山 輝義 [他],三好 隆史,永井 謙一,橋村 孝幸
• 泌尿器科紀要 = Acta urologica Japonica 59(5), 305-308, 2013-05
• … Acquired hemophilia is a rare disease that can result in life threatening bleeding associated with coagulation factor VIII inhibitors. … Further hematological evaluation showed the presence of coagulation factor VIII inhibitors, which led to the diagnosis of acquired hemophilia. … All symptoms disappeared without complication after administration of predonisolone and recombinant activated factor VII. …
• NAID 120005245082

Related Links

• coagulation factor VII - definition of coagulation factor VII by ...

coagulation factor VII Factor VII, see there ... The increased INR values with Neoplastin R during unstable anticoagulation, such as in the initial phase of oral anticoagulation treatment, could be explained by fluctuations in coagulation ...

• Factor VII - Diseases & Conditions - Medscape Reference

Thus, coagulation is a finely regulated system that maintains blood in a fluid phase but can rapidly respond to injury for the formation of clots. Factor VII is a vitamin K–dependent serine protease glycoprotein (also known as stable factor or proconvertin) with a pivotal role in hemostasis and ...

Related Pictures

---

★リンクテーブル★

リンク元	「stable factor」「凝固第VII因子」
拡張検索	「coagulation factor VIIIa」「blood coagulation factor VIII」「blood coagulation factor VII」「coagulation factor VIIa」
関連記事	「fact」「factor」「V」「coagulation factor」

「stable factor」

　　[★] 第VII因子。安定因子

関

blood coagulation factor VII、coagulation factor VII、factor VII、coagulation factors, factor VII

「凝固第VII因子」

　　[★]

英

coagulation factor VII

関

安定因子、第VII因子、血液凝固第VII因子

「coagulation factor VIIIa」

　　[★]

• 活性化凝固第VIII因子、活性化第VIII因子

関

activated factor VIII、factor VIIIa

「blood coagulation factor VIII」

　　[★]

• 血液凝固第VIII因子

関

antihemophilic factor、coagulation factor VIII、factor VIII

「blood coagulation factor VII」

　　[★]

• 血液凝固第VII因子

関

coagulation factor VII、factor VII、stable factor

「coagulation factor VIIa」

　　[★]

• 活性化凝固第VII因子、活性化第VII因子

関

factor VIIa

「fact」

　　[★]

• n.

• 事実、現状、実際、実態

関

actual、actually、in fact、in practice、indeed、practically

　 　 　 　 　

「factor」

　　[★]

• n.

• 因子、要因、要素、ファクター

関

element、elementary、factorial、parameter

　 　 　 　 　 　 　

「V」

　　[★]

• バリン valine
• ビタミン vitamine
• ventilation

　 　

「coagulation factor」

　　[★] 血液凝固因子

同

coagulation factors